David Brian Perez net worth and biography

David Perez Biography and Net Worth

Director of NeoGenomics

With 40 years of executive leadership in medical device and health care services, David Perez serves as an independent board member and advisor to several corporations and non-profit organizations. His expertise encompasses growing and scaling highly regulated global businesses organically through R&D and innovation and inorganically through M&A, leading within a variety of foreign, public and private equity ownership structures, strategic planning, culture and talent development, succession planning, enterprise risk management, operations, compliance, and corporate governance.

What is David Brian Perez's net worth?: The estimated net worth of David Brian Perez is at least $121.70 thousand as of May 5th, 2025. Perez owns 10,000 shares of NeoGenomics stock worth more than $121,700 as of December 5th. This net worth evaluation does not reflect any other assets that Perez may own. Learn More about David Brian Perez's net worth.
How do I contact David Brian Perez?: The corporate mailing address for Perez and other NeoGenomics executives is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. NeoGenomics can also be reached via phone at (239) 768-0600 and via email at [email protected]. Learn More on David Brian Perez's contact information.
Has David Brian Perez been buying or selling shares of NeoGenomics?: David Brian Perez has not been actively trading shares of NeoGenomics in the last ninety days. Most recently, on Monday, May 5th, David Brian Perez bought 10,000 shares of NeoGenomics stock. The stock was acquired at an average cost of $7.63 per share, with a total value of $76,300.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company's stock, valued at $76,300. Learn More on David Brian Perez's trading history.
Who are NeoGenomics' active insiders?: NeoGenomics' insider roster includes (), Douglas Brown (Insider), George Cardoza (Insider), Bruce Crowther (Director), Stephen Kanovsky (Director), Michael Kelly (Director), Mark Mallon (CEO), Kathryn McKenzie (CFO), Alicia Olivo (Executive Vice President, General Counsel & Business Development), David Perez (Director), Jeffrey Sherman (CFO), Robert Shovlin (Insider), Warren Stone (President and Chief Operating Officer), Lynn Tetrault (Director), and Anthony Zook (CEO). Learn More on NeoGenomics' active insiders.
Are insiders buying or selling shares of NeoGenomics?: During the last year, NeoGenomics insiders bought shares 7 times. They purchased a total of 70,600 shares worth more than $550,438.00. During the last year, insiders at the medical research company sold shares 1 times. They sold a total of 20,916 shares worth more than $250,992.00. The most recent insider tranaction occured on November, 25th when EVP Alicia C Olivo sold 20,916 shares worth more than $250,992.00. Insiders at NeoGenomics own 2.4% of the company. Learn More about insider trades at NeoGenomics.
Information on this page was last updated on 11/25/2025.

David Brian Perez Insider Trading History at NeoGenomics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/5/2025	Buy	10,000	$7.63	$76,300.00	10,000

David Brian Perez Buying and Selling Activity at NeoGenomics

NeoGenomics Company Overview

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Today's Range

Now: $12.17

$11.94

$12.26

50 Day Range

MA: $10.21

$7.72

$12.34

2 Week Range

Now: $12.17

$4.72

$19.11

Volume

1,233,955 shs

Average Volume

1,981,554 shs

Market Capitalization

$1.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6